Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer

被引：64

作者：

Gass, Paul ^{[1
]}

Lux, Michael P. ^{[1
]}

Rauh, Claudia ^{[1
]}

Hein, Alexander ^{[1
]}

Bani, Mayada R. ^{[1
]}

Fiessler, Cornelia ^{[2
]}

Hartmann, Arndt ^{[3
]}

Haeberle, Lothar ^{[1
,4
]}

Pretscher, Jutta ^{[1
]}

Erber, Ramona ^{[3
]}

Wachter, David L. ^{[3
]}

Schulz-Wendtland, Ruediger ^{[5
]}

Beckmann, Matthias W. ^{[1
]}

Fasching, Peter A. ^{[1
]}

Wunderle, Marius ^{[1
]}

机构：

[1] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen Univ Hosp, Univ Breast Ctr Franconia, Dept Gynecol & Obstet,Comprehens Canc Ctr Erlange, Univ Str 21-23, D-91054 Erlangen, Germany

[2] Friedrich Alexander Univ Erlangen Nuremberg, Dept Med Informat Biometry & Epidemiol, Waldstr 6, D-91054 Erlangen, Germany

[3] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen Univ Hosp, Inst Pathol, Krankenhausstr8-10, D-91054 Erlangen, Germany

[4] Erlangen Univ Hosp, Biostat Unit, Dept Gynecol & Obstet, Univ Str 21-23, D-91054 Erlangen, Germany

[5] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen Univ Hosp, Inst Diagnost Radiol, Maximilianspl 3, D-91054 Erlangen, Germany

来源：

BMC CANCER | 2018年 / 18卷

关键词：

Triple-negative breast cancer; Neoadjuvant therapy; Platinum; Pathological complete response; Prognosis; Prediction; HOMOLOGOUS RECOMBINATION DEFICIENCY; DNA-REPAIR; CHEMOTHERAPY; BRCA1; MUTATION; CARBOPLATIN; SURVIVAL; THERAPY; RATES; CARE;

D O I：

10.1186/s12885-018-4925-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundIt has been reported that pathological complete response is an important surrogate marker for disease-free survival and overall survival in patients with triple-negative breast cancer. This study investigates predictors of the response to neoadjuvant platinum-based or anthracycline-based treatment, and of the prognosis, in patients with triple-negative breast cancer.MethodsA total of 121 patients with triple-negative breast cancer received neoadjuvant treatment with either platinum or anthracycline between 2008 and 2013. Pathological complete response was assessed relative to different treatments using logistic regression models with age, clinical tumor stage, grading, and Ki-67 as predictors and interaction terms, to obtain adjusted and subgroup-specific results. The impact of the pathological complete response rate on disease-free survival and overall survival was also analyzed.ResultsThe pathological complete response rate was higher after platinum/taxane treatment compared with anthracycline/taxane (50.0% vs. 41.8%), but this was not significant in the adjusted analysis (OR 1.44; 95% CI, 0.68 to 3.09). A high histological grade (G3) was a predictor for higher pathological complete response in platinum-based therapy (OR 2.27; 95% CI, 1.00 to 5.30). The effect of neoadjuvant chemotherapy on pathological complete response was significantly different for G1-2 vs. G3 (P-interaction=0.013), and additional subgroup-specific differences were noted. Pathological complete response was a predictor for improved disease-free survival and overall survival in both treatment groups, with and without platinum chemotherapy.ConclusionsThis retrospective study of patients with triple-negative breast cancer adds to the evidence that the treatment effect of platinum may be greatest particularly in G3 tumors. In addition, the effect of pathological complete response on the prognosis does not depend on the treatment used.

引用

页数：8

共 61 条

[1] Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study [J].

Balmativola, D. ;

Marchio, C. ;

Maule, M. ;

Chiusa, L. ;

Annaratone, L. ;

Maletta, F. ;

Montemurro, F. ;

Kulka, J. ;

Figueiredo, P. ;

Varga, Z. ;

Liepniece-Karele, I. ;

Cserni, G. ;

Arkoumani, E. ;

Amendoeira, I. ;

Callagy, G. ;

Reiner-Concin, A. ;

Cordoba, A. ;

Bianchi, S. ;

Decker, T. ;

Glaeser, D. ;

Focke, C. ;

van Diest, P. ;

Grabau, D. ;

Lips, E. ;

Wesseling, J. ;

Arisio, R. ;

Medico, E. ;

Wells, C. ;

Sapino, A. .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (03) :511-523

[2] Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis [J].

Bareche, Y. ;

Venet, D. ;

Ignatiadis, M. ;

Aftimos, P. ;

Piccart, M. ;

Rothe, F. ;

Sotiriou, C. .

ANNALS OF ONCOLOGY, 2018, 29 (04) :895-902

[3] Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients [J].

Beckmann, Matthias W. ;

Brucker, Cosima ;

Hanf, Volker ;

Rauh, Claudia ;

Bani, Mayada R. ;

Knob, Stefanie ;

Petsch, Sabrina ;

Schick, Stefan ;

Fasching, Peter A. ;

Hartmann, Arndt ;

Lux, Michael P. ;

Haeberle, Lothar .

ONKOLOGIE, 2011, 34 (07) :362-367

[4] Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer [J].

Beheshti, Farimah ;

Hassanian, Seyed Mahdi ;

Khazaei, Majid ;

Hosseini, Mahmoud ;

ShahidSales, Soodabeh ;

Hasanzadeh, Malihe ;

Maftouh, Mina ;

Ferns, Gordon A. ;

Avan, Amir .

JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (04) :2752-2758

[5] The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers [J].

Bertucci, Francois ;

Finetti, Pascal ;

Birnbaum, Daniel ;

Mamessier, Emilie .

ONCOIMMUNOLOGY, 2016, 5 (03)

[6] The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].

Bhattacharyya, A ;

Ear, US ;

Koller, BH ;

Weichselbaum, RR ;

Bishop, DK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903

[7] Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? [J].

Brenton, JD ;

Carey, LA ;

Ahmed, AA ;

Caldas, C .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (29) :7350-7360

[8] Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy [J].

Byrski, Tomasz ;

Gronwald, Jacek ;

Huzarski, Tomasz ;

Grzybowska, Ewa ;

Budryk, Magdalena ;

Stawicka, Malgorzata ;

Mierzwa, Tomasz ;

Szwiec, Marek ;

Wisniowski, Rafal ;

Siolek, Monika ;

Dent, Rebecca ;

Lubinski, Jan ;

Narod, Steven .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :375-379

[9] The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis [J].

Chen, Xianyu ;

He, Chao ;

Han, Dongdong ;

Zhou, Meirong ;

Wang, Quan ;

Tian, Jinhui ;

Li, Lun ;

Xu, Feng ;

Zhou, Enxiang ;

Yang, Kehu .

FUTURE ONCOLOGY, 2017, 13 (09) :843-857

[10] Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer [J].

Couch, Fergus J. ;

Hart, Steven N. ;

Sharma, Priyanka ;

Toland, Amanda Ewart ;

Wang, Xianshu ;

Miron, Penelope ;

Olson, Janet E. ;

Godwin, Andrew K. ;

Pankratz, V. Shane ;

Olswold, Curtis ;

Slettedahl, Seth ;

Hallberg, Emily ;

Guidugli, Lucia ;

Davila, Jaime I. ;

Beckmann, Matthias W. ;

Janni, Wolfgang ;

Rack, Brigitte ;

Ekici, Arif B. ;

Slamon, Dennis J. ;

Konstantopoulou, Irene ;

Fostira, Florentia ;

Vratimos, Athanassios ;

Fountzilas, George ;

Pelttari, Liisa M. ;

Tapper, William J. ;

Durcan, Lorraine ;

Cross, Simon S. ;

Pilarski, Robert ;

Shapiro, Charles L. ;

Klemp, Jennifer ;

Yao, Song ;

Garber, Judy ;

Cox, Angela ;

Brauch, Hiltrud ;

Ambrosone, Christine ;

Nevanlinna, Heli ;

Yannoukakos, Drakoulis ;

Slager, Susan L. ;

Vachon, Celine M. ;

Eccles, Diana M. ;

Fasching, Peter A. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (04) :304-U154

← 1 2 3 4 5 6 7 →